

HOW DO YOU ASSESS EARLY SIGNS OF RESISTANCE?

Susan enjoys volunteering and spending time with her family. She wants to get back to focusing on the joys of her daily life.

Sokal risk score	Intermediate risk (1.2)
Time since diagnosis	15 months
Current treatment	2nd-line TKI
Length of time on current treatment	3 months
Molecular status	12% BCR-ABL1
Persistent AE	Grade 2 rash

- Susan is showing early signs of potential resistance to her current treatment. How would you evaluate the appropriate CML treatment approach for a patient like Susan?
- According to the National Comprehensive Cancer Network® (NCCN®), patients with >10% BCR-ABL1 at 3 months have possible TKI resistance¹
- According to European LeukemiaNet (ELN) recommendations, patients with >10% BCR-ABL1 at 3 months should be carefully considered for continuation or change of treatment, depending on patient characteristics, comorbidities, and tolerance²

LEARN ABOUT UNMET NEEDS IN CML. [VISIT OUR SITE](#)

TARGETCML

AE, adverse event; CML, chronic myeloid leukemia; TKI, tyrosine kinase inhibitor.

References: 1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Chronic Myeloid Leukemia V3.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed April 15, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

2. Hochhaus A, Baccarani M, Silver RT, et al. *Leukemia*. 2020;34:966-984.

 **NOVARTIS**

Novartis Pharma AG
CH-4002 Basel Switzerland

© 2022 Novartis

5/22

205165

Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936-1080

Patient portrayal.

